MX2021010848A - Reduccion de la dosis de antibioticos en composiciones de antibioticos/antiinflamatorios combinados para uso oftalmico. - Google Patents

Reduccion de la dosis de antibioticos en composiciones de antibioticos/antiinflamatorios combinados para uso oftalmico.

Info

Publication number
MX2021010848A
MX2021010848A MX2021010848A MX2021010848A MX2021010848A MX 2021010848 A MX2021010848 A MX 2021010848A MX 2021010848 A MX2021010848 A MX 2021010848A MX 2021010848 A MX2021010848 A MX 2021010848A MX 2021010848 A MX2021010848 A MX 2021010848A
Authority
MX
Mexico
Prior art keywords
antibiotic
combined together
reduction
dosage
ophthalmic use
Prior art date
Application number
MX2021010848A
Other languages
English (en)
Inventor
Federico Bertocchi
Luciano Marcelloni
Marino Carnovali
Original Assignee
Ntc S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ntc S R L filed Critical Ntc S R L
Publication of MX2021010848A publication Critical patent/MX2021010848A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición oftálmica que comprende una mezcla que comprende, o, como alternativa, que consiste en un antibiótico y un corticosteroide, y, opcionalmente, uno o más aditivos y excipientes de calidad farmacéutica; siendo dicha composición para su uso en un procedimiento para la profilaxis de infecciones posquirúrgicas y el tratamiento de eventos inflamatorios en un paciente previamente sometido a cirugía ocular, preferentemente cirugía de cataratas. La presente invención se refiere a un procedimiento para reducir la dosis de antibióticos en composiciones antibióticas/antiinflamatorias combinadas para uso oftálmico.
MX2021010848A 2019-03-11 2020-03-10 Reduccion de la dosis de antibioticos en composiciones de antibioticos/antiinflamatorios combinados para uso oftalmico. MX2021010848A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102019000003529A IT201900003529A1 (it) 2019-03-11 2019-03-11 Riduzione della posologia antibiotica in composizioni antibiotico/antinfiammatorio in associazione tra loro per uso oftalmico
PCT/IB2020/052057 WO2020183361A1 (en) 2019-03-11 2020-03-10 Reduction of antibiotic dosage in antibiotic/anti-inflammatory compositions combined together for ophthalmic use

Publications (1)

Publication Number Publication Date
MX2021010848A true MX2021010848A (es) 2022-01-19

Family

ID=66867655

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010848A MX2021010848A (es) 2019-03-11 2020-03-10 Reduccion de la dosis de antibioticos en composiciones de antibioticos/antiinflamatorios combinados para uso oftalmico.

Country Status (9)

Country Link
EP (1) EP3937903A1 (es)
CN (1) CN113710227A (es)
AU (1) AU2020236730A1 (es)
BR (1) BR112021017238A2 (es)
CA (1) CA3131993A1 (es)
IT (1) IT201900003529A1 (es)
MA (1) MA55293A (es)
MX (1) MX2021010848A (es)
WO (1) WO2020183361A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE122564T1 (de) * 1988-03-09 1995-06-15 Alcon Lab Inc Kombinierung von tobramycin und steroiden für topische ophthalmische verwendung.
DE19729879C2 (de) * 1997-07-11 1999-07-08 Mann Gerhard Chem Pharm Fab Lagerstabile ophthalmische Zusammensetzungen, umfassend Diclofenac und Ofloxacin
CN110339153A (zh) * 2013-05-24 2019-10-18 爱康生物科技有限公司 地塞米松单位剂型、试剂盒及白内障手术后炎症中的应用
EP4026537A1 (en) * 2014-11-07 2022-07-13 Santen Pharmaceutical Co., Ltd. Ophthalmic aqueous composition

Also Published As

Publication number Publication date
WO2020183361A1 (en) 2020-09-17
MA55293A (fr) 2022-04-06
AU2020236730A1 (en) 2021-09-16
CN113710227A (zh) 2021-11-26
EP3937903A1 (en) 2022-01-19
BR112021017238A2 (pt) 2021-11-09
IT201900003529A1 (it) 2020-09-11
CA3131993A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
EP3693369A3 (en) Bromodomain inhibitors
MY196599A (en) Pharmaceutical compositons comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
MX2019013799A (es) Peptido novedoso y composicion farmaceutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmaceutico activo.
MX2021006884A (es) Compuestos y su uso para el tratamiento de la deficiencia de alfa1-antitripsina.
WO2021168483A3 (en) Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors
MX2020009235A (es) Formulacion oftalmica.
MY162494A (en) Solid pharmaceutical compositions containing an integrase inhibitor
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
MX2022008479A (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
WO2016168553A8 (en) Deuterated obeticholic acid
EP3921420A4 (en) DRUG DELIVERY COMPOSITIONS FOR OCULAR DELIVERY OF THERAPEUTIC AGENTS AND METHODS OF USE THEREOF
NZ766141A (en) Isoxazoline parasiticide formulations and methods for treating blepharitis
NZ751972A (en) Treatment of prurigo nodularis
EP3856172A4 (en) PHARMACEUTICALLY ACTIVE CANNABIS-BASED COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF GASTROINTESTINAL CONDITIONS
MX2020008360A (es) Forma cristalina de bictegravir sodico.
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
MX2021010848A (es) Reduccion de la dosis de antibioticos en composiciones de antibioticos/antiinflamatorios combinados para uso oftalmico.
MX2021015441A (es) Formas cristalinas de cabotegravir de sodio.
MX2023011546A (es) Composiciones nasales que comprenden alcaftadina.
MX2023002907A (es) Compuestos heterociclicos como inhibidores del bromodominio cbp/ep300.
MX2021016055A (es) Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis.
MX2022004806A (es) Metodos y composiciones para tratar la anemia drepanocitica con un inhibidor de la ferroportina (vit-2763).
WO2018234871A3 (en) COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE
EA202091523A1 (ru) Терапевтический агент для лечения глаукомы, содержащий агонист fp-рецепторов и -блокатор
WO2017100378A3 (en) Vaginal inserted estradiol pharmaceutical compositions and methods